Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.

A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.

Tevogen Bio believes that its highly purified antigen specific T cell investigational therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A

Scientists from the Gladstone Institutes discover how to enhance the longevity of cells that kill tumors and infected cells